EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review

Agni M Konitsioti, Harald Prüss, Sarah Laurent, Gereon R Fink, Christoph Heesen, Clemens Warnke

Journal of Neurology · 2024-10 · 271 (10) · 6526-6542

DOI: 10.1007/s00415-024-12642-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Neurology, online erschienen am 14.09.2024. Verfasst von Agni M Konitsioti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. agni.konitsioti@uk-koeln.de. Hauptthemen laut MEDLINE: Autoimmune Diseases of the Nervous System, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance B-cell-targeting monoclonal antibodies have demonstrated safety and efficacy in multiple sclerosis or anti-aquaporin-4 IgG positive neuromyelitis optica spectrum disorder. However, these therapies do not facilitate drug-free remission, which may become possible with cell-based therapies, including chimeric antigen receptor (CAR) T cells. CAR T-cell therapy holds promise for addressing other antibody-mediated CNS disorders, e.g., MOG-associated disease or autoimmune encephalitis.

Objective

To provide an overview of the current clinical knowledge on CAR T-cell therapy in central nervous system autoimmunity. Evidence review We searched PubMed, Embase, Google Scholar, PsycINFO, and clinicaltrials.gov using the terms ‘CAR T cell’ and ‘multiple sclerosis/MS’ or ‘neuromyelitis optica/spectrum diseases/NMOSD’ or ‘MOG-associated disease/MOGAD ‘or’ autoimmune encephalitis’ or ‘neuroimmunology’.

Findings

An ongoing phase I clinical trial has indicated the safety and benefits of anti-BCMA CAR T cells in 12 patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder. Case reports involving two individuals with progressive multiple sclerosis and one patient with stiff-person syndrome demonstrated a manageable safety profile following treatment with anti-CD19 CAR T cells. Recruitment has commenced for two larger studies in MS, and a phase I open-label basket study is underway to evaluate BCMA-directed CAR T cells in various antibody-associated inflammatory diseases, including MOG-associated disease. Preclinical research on NMDA receptor antibody autoimmune encephalitis treated with chimeric autoantibody receptor T cells generated promising data. Conclusions and relevance There is minimal evidence of the benefits of CAR T-cell therapy in individuals with central nervous system-directed autoimmunity. Nevertheless, multicenter controlled clinical trials with a manageable safety profile appear feasible and are warranted due to very promising case experiences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune Diseases of the Nervous SystemImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansT-Lymphocytes

Stichwörter der Autor:innen

Antibody-mediated CNS disordersCAR T-cell therapyCentral nervous system autoimmunityMultiple sclerosisNMOSD

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. agni.konitsioti@uk-koeln.de.
  • Faculty of Medicine, University Hospital Cologne, Cologne, Germany. agni.konitsioti@uk-koeln.de.
  • Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
  • Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM3), Research Center Jülich, Jülich, Germany.

Förderung

  • Universitätsklinikum Köln

Zitieren

APA

Konitsioti, A. M., Prüss, H., Laurent, S., Fink, G. R., Heesen, C., & Warnke, C. (2024). Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review. Journal of Neurology, 271(10), 6526-6542. https://doi.org/10.1007/s00415-024-12642-4

Vancouver

Konitsioti AM, Prüss H, Laurent S, Fink GR, Heesen C, Warnke C. Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review. Journal of Neurology. 2024;271(10):6526-6542. doi:10.1007/s00415-024-12642-4

BibTeX
@article{Konitsioti2024,
  author = {Konitsioti, Agni M and Prüss, Harald and Laurent, Sarah and Fink, Gereon R and Heesen, Christoph and Warnke, Clemens},
  title = {Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review},
  journal = {Journal of Neurology},
  year = {2024},
  volume = {271},
  number = {10},
  pages = {6526--6542},
  doi = {10.1007/s00415-024-12642-4}
}
Kostenlos starten →